Hearing impairment is the most common sensory deficit. It is frequently caused by the expression of an allele carrying a single dominant missense mutation. Herein, we show that a single intracochlear injection of an artificial microRNA carried in a viral vector can slow progression of hearing loss for up to 35 weeks in the Beethoven mouse, a murine model of non-syndromic human deafness caused by a dominant gain-of-function mutation in Tmc1 (transmembrane channel-like 1). This outcome is noteworthy because it demonstrates the feasibility of RNA-interference-mediated suppression of an endogenous deafness-causing allele to slow progression of hearing loss. Given that most autosomal-dominant non-syndromic hearing loss in humans is caused by this mechanism of action, microRNA-based therapeutics might be broadly applicable as a therapy for this type of deafness.
Introduction
Hearing impairment is the most common sensory deficit. It affects more than 360 million people worldwide and broadly impacts their quality of life (see Web Resources). 1 Not only does it limit the ability to interpret speech sounds (leading to delayed language acquisition in infancy), but in adulthood hearing impairment can lead to economic disadvantage, social isolation, and stigmatization. Current treatment options focus on hearing aids and cochlear implants to bypass the biologic deficit by amplifying sounds (hearing aids) or by encoding them as electrical impulses that are transmitted to the auditory nerve through an implanted electrode array (cochlear implants). Although these two habilitation options are effective, they do not restore ''normal'' hearing. As life expectancy improves and populations grow, the hearing-impaired population will increase, making the development of therapeutics to restore or prevent hearing loss important to enhancing quality of life. 2 Over the past decade, we have focused on RNA interference (RNAi) as a means of selectively suppressing mutant alleles in animal models of deafness. 3, 4 Herein, we report on the use of an artificial microRNA (miRNA)-based approach to rescuing the progressive hearing-loss phenotype in the Beethoven (Bth) mutant mouse, a mouse model of human autosomal-dominant non-syndromic hearing loss (DFNA36 [MIM: 606705] ). This mouse carries the semi-dominant Tmc1 c.1235T>A (p.Met412Lys) allele. 5 The encoded protein, TMC1, is a transmembrane protein with six hydrophobic transmembrane domains ( Figure 1A ). 7 TMC1 interacts with the tip-link proteins protocadherin 15 and cadherin 23 and, together with TMC2, is assumed to be a component of the mechanoelectrical transduction complex. 8, 9 Five mutations have been reported in the human homolog, TMC1 (MIM: 606706], to cause autosomal-dominant non-syndromic hearing loss at the DFNA36 locus. [10] [11] [12] [13] [14] [15] One TMC1 mutation, c.1253T>A (p.Met418Lys) (GenBank: NM_138691, NCBI build 36.3), is orthologous to the murine Bth mutation (Tmc1 c.1235T>A [p.Met412Lys]) and segregates in a large, 222 member Chinese family who suffers from progressive post-lingual sensorineural hearing loss ( Figure 1B ). In this kindred, age of onset varies from 5 to 25 years, potentially providing a window for therapeutic intervention to prevent the otherwise inevitable deterioration of hearing thresholds, which by 50 years of age are in the severe-toprofound range across all frequencies. 15 This natural pro-of Iowa Institutional Animal Care and Use Committee (protocol 0608169) approved all relevant procedures.
Mice
All procedures met NIH guidelines for the care and use of laboratory animals and were approved by the Institutional Animal Care and Use Committee at the University of Iowa. Mice were housed in a temperature-controlled environment on a 12 hr light-dark cycle. Food and water were provided ad libitum. Isogenic Bth-heterozygous mice (Tmc1
) maintained on a C3HeB/FeJ (C3H) background were obtained as a gift from Dr. Karen Steel. 5 Inbred wild-type C3H mice were obtained from the ) and maintained on a C57BL/6J background as previously described. 16 
RNAi Oligonucleotide Constructs
The RNAi oligonucleotides and vector plasmids were designed by the Viral Vector Core at the University of Iowa. Fifteen small interfering RNA (siRNA) sequences, either hand designed or selected with siSPOTR (siRNA Seed Probability of Off-Target Reduction) software, were chosen for walking through the target sequence one base at a time 17 (Table S1 ). Forward and reverse oligonucleotide primers, which included an overlap in the common loop of the miRNA, were purchased from Integrated DNA Technologies and used for creating artificial miRNAs. The artificial-miRNA expression cassette was generated by PCR, purified, and digested as previously described. 17, 18 Each artificial-miRNA expression cassette was cloned into a vector plasmid flanked by inverted terminal repeat sequences and containing the mouse U6 promoter (mU6) followed by a multiple-cloning site, cytomegalovirus (CMV)-promoter-driven eGFP, and a Pol II termination signal. miSafe, a sequence specifically selected for its validated low off-targeting potential, was used as a control. 6 Virus Production AAV vectors were prepared by the Viral Vector Core at the University of Iowa by a standard triple-transfection method in 293FT cells and subsequent purification in a cesium chloride gradient as previously described. 19 For vector selection, single-stranded recombinant AAV serotypes (rAAV2/1 and rAAV2/9) that carried CMV-driven eGFP (rAAV2/1eGFP and rAAV2/9eGFP) were tested. Viral titers used in trans-round-window-membrane (RWM) injections were rAAV2/1 at 3.09 3 10 13 vg/ml and rAAV2/9 at 1.59 3 10 13 vg/ml. The selected therapeutic was Bth/þ mouse. (C) siRNA sequence #16 embedded in an artificial miRNA scaffold. Of all miRNAs tested, #16 had the most specific and selective suppression of the mutant Tmc1 c.1235T>A allele. Blue and red arrows depict predicted Drosha and Dicer cleavage sites, respectively; the dashed box shows the core #16 sequence targeting the mutant Tmc1 variant. (D) Real-time qPCR analysis of total RNA isolated from COS-7 cells cotransfected with constructs expressing both miRNA #16 and miSafe (a sequence specifically selected for its validated low off-targeting potential 6 ) and either wild-type Tmc1 or mutant Tmc1 c.1235T>A. Relative mRNA expression levels were calculated with the DDCt algorithm. Error bars represent the SD of three biological and nine technical replicates.
single-stranded recombinant AAV serotype 2/9 (rAAV2/9) carrying a dual transgene cassette of mouse U6-driven miRNA #16, targeting the p.Met412Lys-encoding allele and downstream CMVdriven eGFP (rAAV2/9miTmc1k412.16eGFP [miTmc] ). The control vector was mU6-driven miSafe and downstream CMV-driven eGFP (rAAV2/9miSafeGFP [miSafe]). 6 Vector titers were determined by real-time PCR and were miTmc at 1.69 3 10 12 and miSafe at 1.39 3 10 13 DNase-resistant particles per mililiter. Virus aliquots were stored at À80 C before use.
Viral Inoculation
All mice were operated on at postnatal days 0-2 (P0-P2) under hypothermic anesthesia, for which animals were placed in a container with crushed ice for 3-5 min. trans-RWM injections were performed under an operating microscope. First, a post-auricular incision exposed the cochlea bulla, which was opened with fine forceps. Anatomic landmarks included the RWM and stapedial artery, which were identified before injections ( Figure S1 ). Then, for the trans-RWM injection, either miTmc or miSafe mixed in a 10:1 ratio with 2.5% fast green dye was loaded into a borosilicate glass pipette (1.5 mm outer diameter [OD] 3 0.86 mm inner diameter [ID] , Harvard Apparatus) pulled with a Sutter P-97 micropipette puller to a final OD of~20 mm and affixed to an automated injection system pressured by compressed gas (Harvard Apparatus). Pipettes were manually controlled with a micropipette manipulator. A total volume of 0.5 ml was injected into the left ear of each mouse. After all procedures, mice were placed on a heating pad for recovery and rubbed with bedding before being returned to the mother. Recovery was closely monitored daily for at least 5 days post-operatively.
Auditory Testing
The hearing thresholds were recorded in the following groups: (1) wild-type littermates (C3HeB/FeJ inbred mice: n ¼ 4 from 4 to 13 weeks; n ¼ 5 from 26 to 35 weeks), (2) Tmc1 Bth/þ non-injected mice (n ¼ 11), (3) Tmc1 Bth/þ þmiSafe mice (n ¼ 13), and (4) rescued
Tmc1
Bth/þ þmiTmc mice (n ¼ 10). Auditory testing was conducted in a sound-attenuating room. Stimulus presentation and recording were controlled with MATLAB software (MathWorks) running on a PC connected to a 24-bit external sound card (Motu UltraLite mk3) as previously described. 20 Stimuli were delivered via an ER-10Bþ probe micro- Figure S2A . This method of calibration differs from that of many previous studies that used a standard 2 cm 3 coupler ( Figure S2B ). For a given voltage drive to the loudspeaker, the sound pressure measured in the smaller cavity will be much larger than that measured in a 2 cm 3 coupler. We based our calibration on the smaller cavity under the assumption that the actual pressure experienced at the mouse tympanic membrane is most accurately represented with a cavity that approximates the size of the mouse ear canal rather than the standard 2 cm 3 coupler, which approximates a human ear canal. Measurements in our laboratory showed a 27 dB difference between pressures measured in the smaller (0.028 cm 3 ) and larger (2 cm 3 ) couplers. Therefore, when an auditory-brainstemresponse (ABR) threshold is found, the reported sound pressure delivered by the loudspeaker will depend on the calibration cavity used. For identical thresholds, the values reported for the smaller coupler will be 27 dB higher (apparently worse) than the values reported for the larger coupler. Although the smallcoupler values might reflect sound pressures delivered to the mouse eardrum more accurately, for ease of direct comparison to previous studies using C3HeB/FeJ mice, we report ABR thresholds in terms of equivalent 2 cm 3 coupler values.
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ABR
Mice were anesthetized with intraperitoneal ketamine and xylazine at 100 and 6 mg per kg of body weight, respectively. ABR thresholds were obtained for both clicks and tone bursts. Clicks were square pulses 100 ms in duration. Tone bursts were 3 ms in length, including 1 ms onset and offset ramps (raised cosine shape) centered at 8, 16, and 32 kHz. The sweep length for each stimulus (both click and tone burst) was 29 ms. Between 500 and 1,000 sweeps were averaged at each stimulus level for obtaining the ABR waveforms. All recordings were conducted from both ears of all animals in a sound-attenuating room.
Distortion-Product Otoacoustic Emissions
Distortion-product otoacoustic emissions (DPOAEs) at 2f1 À f2 were measured with f2 frequencies from 4 to 32 kHz in half-octave steps (f2/f1 ¼ 1.22). The levels of the primaries were fixed at 65 and 55 dB sound-pressure level (SPL) for f1 and f2, respectively. For each f2 frequency, ten 1 s stimulus presentations were averaged. DPOAE amplitudes and associated noise floors were calculated from fast-Fourier-transform (FFT) analysis of the averaged waveforms.
Immunohistochemistry and Histology
All injected and non-injected cochleae were harvested after animals were sacrificed by CO 2 inhalation. Temporal bones were removed, perfused with 4% paraformaldehyde, and incubated for 1 hr. Cochleae were then rinsed in PBS and stored at 4 C in preparation for dissection and immunohistochemistry. Specimens were visualized with a dissecting microscope and dissected as previously described. 22 Specimens were infiltrated with 0.3% Triton X-100 and blocked with 5% normal goat serum before tissues were incubated first in rabbit polyclonal Myosin-VIIA antibody (Proteus Biosciences) or mouse monoclonal antibody to GFP (Millipore) diluted at 1:1,000 in PBS for 1 hr and then in a 1:1,000 dilution of the secondary antibody, fluorescence-labeled anti-rabbit IgG Alexa Fluor 568 or goat anti-mouse IgG Alexa Flour 488 in a 1:2,000 dilution (Invitrogen, Molecular Probes) for 30 min. Filamentous actin was labeled by a 30 min incubation of phalloidin conjugated to Alexa Fluor 488 (Invitrogen, Molecular Probes). Specimens were mounted in ProLong Diamond mounting medium (Life Technologies). z stack images of whole mounts were collected at 103-403 on a Leica SP8 confocal microscope (Leica Microsystems). Maximumintensity projections of z stacks were generated for each field of view, and composite images showing the whole cochlea were constructed in Adobe Photoshop CS6 in order to meet equal conditions and show the complete turns of the cochlea at high resolution. Distance from the apex was measured in 0.25 or 0.40 mm segments with imageJ (NIH Image). For the viral-vector-screening study, inner hair cells (IHCs) and outer hair cells (OHCs) with positive eGFP and overlapping MYO7A were counted with ImageJ Cell Counter. The total number of hair cells and GFP-positive hair cells were summed and converted to a percentage. For the miRNA study, IHCs and OHCs with positive MYO7A were counted with ImageJ Cell Counter; any segments that contained dissection-related damage were omitted from the analysis. IHC and OHC survival was quantified with 203-403 images of whole-mount cochleae compiled into cochleograms at 35 weeks as previously described. 23 
Molecular Studies for In Vitro and In Vivo Expression Analyses
Previously reported cDNAs p.AcGFPmTmc1ex1WT and p.GEMTeasyTmc1ex1Bth were provided by Dr. Andrew Griffith. p.GEMTeasyTmc1ex1Bth was PCR amplified with forward (5 0 -GTCGACAG GATGCCACCCAAAAAAG-3 0 ) and reverse (5 0 -ATGGATCCACTG GCCACCAGCAGC-3 0 ) primers containing restriction sites SalI and BamH1. cDNA inserts were purified by 1% agarose gel electrophoresis and QIAquick Gel Extraction (QIAGEN) and subcloned and ligated into SalI-and BamH-digested p.AcGFP1-N2 vector (catalog no. 632483, Takara Clontech). Successful cloning was verified with Sanger sequencing (ABI PRISM model 3730XL, Applied Biosystems). For in vitro miRNA screening, the aforementioned miRNA expression plasmids were used. COS-7 cells, which do not contain native TMC1, were used in this study and grown in DMEM (Invitrogen, Thermo Fisher Scientific) with 10% fetal bovine serum at 37 C with 5% CO 2 . 7 Prior to transfection, COS-7 cells were transferred and grown on a 24-well plate for 1 day. mice was injected with rAAV2/9 carrying miTmc; the right ear served as a non-injected control. Cochleae were harvested at P28. eGFP localization in hair cells was confirmed in the apical turns, which was dissected with a fluorescence dissecting micoscope. Cochlear tissue was incubated for 5 min in a collagenase solution at room temperature as previously described. 24 To isolate populations of eGFP-positive hair cells, we isolated hair cells with a pulled glass micropipette as previously described 24 and added a wash step prior to final collection (Movie S1). We changed glass pipettes after each isolation to minimize the introduction of contaminating RNAs into the lysis buffer from either the isolation buffer or previously isolated cells. GFP-positive hair cells were isolated and placed into tubes containing lysis buffer as previously described. 25 Smart-seq2 protocol steps 1-13 were followed directly for sample processing from lysis through reverse transcription; however, the number of cycles in the PCR pre-amplification (step 14) was reduced to 7 for the purpose of minimizing amplification bias. The resulting product was used as the input for SYBR Green-based qRT-PCR. Allele-specific Bth (5 0 -AAACAGGGTGGGA CAGAACþT-3 0 ) and wild-type Tmc1 (5 0 -AAACAGGGTGGGACAG AACþA-3 0 ) reverse primers were designed with Locked Nucleic Acid-modified nucleotides on the 3 0 end, denoted as þT or þA. . Hair bundles were deflected with stiff glass probes fabricated from capillary glass with a fire polisher (World Precision Instruments) for creating a rounded probe tip of~3-5 mm in diameter. Probes were mounted on a PICMA Chip piezo actuator (Physik Instrumente) and driven by a 400 mA ENV400 amplifier (Piezosystem). Sensory-transduction currents were recorded without knowledge of GFP expression from control and miTmc-treated hair cells. The data were filtered at 10 kHz with a low-pass Bessel filter and digitized at R20 kHz with a 16-bit acquisition board (Digidata 1440A, Molecular Devices) and pClamp 10 software (Molecular Devices). Data were stored for offline analysis with OriginPro 8 (OriginLab).
Statistical Analysis
Statistical analysis of ABR, DPOAE, and cell-counting data was completed in R with two-sample t tests for samples of equal variance. Samples with unequal variance were compared with Welch two-sample t tests. Sample variance was determined with F tests comparing two variances. All comparisons were made between the Tmc1
Bth/þ þmiTmc and Tmc1
Bth/þ þmiSafe cohorts.
Results
RNAi Suppresses the Tmc1 c.1235T>A Allele We sought to prevent progression of hearing loss in Tmc1 Bth/þ mice by using an artificial miRNA to suppress the expression of the mutant Tmc1 c.1235T>A allele. Of 15 miRNA constructs evaluated (Table S1 ), one miRNA, #16, was chosen for further study because it robustly and selectively suppressed the Tmc1 c.1235A allele without affecting the wild-type allele ( Figures 1C and 1D) . We chose to use rAAV2/9 as the delivery vector after we compared the transduction efficiency of rAAV2/1-eGFP and rAAV2/9-eGFP injection into the cochleae of wildtype mice at P0-P2 by a trans-RWM approach. At 2 weeks, rAAV2/1-eGFP localized to a variety of cell types, including robust localization in supporting cells; rAAV2/9-eGFP, in comparison, predominantly localized to IHCs, which were transduced with 74% efficiency in the apical cochlear turn (Figures 2A and 2B) . The corresponding transduction of OHCs was 7%. Because IHC dysfunction is primarily responsible for the deafness phenotype in Tmc1 Bth/þ animals and OHC loss is subtle in the apical cochlear turns, 5, 26 we considered the observed levels of hair cell transduction acceptable for this study. The miRNA #16 expression cassette was cloned into rAAV2/9 as a dual transgene cassette of mouse U6-driven miRNA targeting the p.Met412Lys-encoding transcript coupled upstream of CMV-driven eGFP (rAAV2/ 9miTmck412.16eGFP, miTmc). A control vector was designed to carry a U6-driven specific sequence selected for its validated low off-targeting potential and CMV-driven eGFP (miSafe) 6 ( Figure 3A) . trans-RWM inoculation surgery, whereby 0.5 ml of miTmc or miSafe was injected into only the left cochlea, was performed on Tmc1
Bth/þ mice at P0-P2 ( Figure S1 ). We verified robust IHC eGFP localization in cochleae harvested from Tmc1
Bth/þ P0-P2 miTmc-injected mice 2 weeks after surgery, consistent with the transduction pattern observed in ears injected with rAAV2/9-eGFP ( Figure 3B ; Figure S3 ). To assess in vivo allele-specific suppression in individual hair cells, 4 weeks after surgery we isolated GFP-positive hair cells from miTmc-injected cochleae and control hair cells from contralateral non-injected cochleae and completed real-time qPCR by using primers specific to the wild-type and Bth Tmc1 alleles (Movie S1). In non-injected ears, the relative expression of the Bth Tmc1 c.1235T>A allele and the wild-type allele was comparable ( Figure 3C ). In biological replicates from miTmc-injected ears, expression of the Bth Tmc1 c.1235T>A allele was suppressed by more than 88% in comparison to levels of Bth mRNA detected in the sample from the untreated contralateral ear (Figures 3C).
Mechanotransduction TMC1 and its closely related ortholog, TMC2, are assumed to be components of the mechanotransduction channel.
In an earlier report, the mutant TMC1 p.Met412Lys variant was found to reduce calcium permeability and single-channel currents in IHCs. 16 To test the effect of RNAi and allele- Bth/þ þmiTmc mice. ABR thresholds were assessed as a response to both clicks and tone bursts at 8-32 kHz, whereas DPOAEs were measured at halfoctave intervals across the same frequency range.
Click ABRs cover a broad frequency and stimulus range (2-8 kHz and up to 90 dB SPL). We tested animals at 4 week intervals for 35 weeks and documented the expected deterioration of hearing thresholds in Tmc1 Bth/þ mice, which by 17-21 weeks of age had hearing in the severe-to-profound range ( Figure S4 ). The rate and degree of hearing loss were consistent with those reported by Noguchi and colleagues and were also seen in the untreated contralateral right ears of Tmc1
Bth/þ þmiTmc mice and in the injected left ears of Tmc1 Bth/þ þmiSafe mice, demonstrating that neither the viral inoculation procedure nor the vector itself added to the decline in auditory function 26 ( Figure 5B ).
The progression of hearing loss was slower in the injected left ears of Tmc1
Bth/þ þmiTmc mice. In all
Tmc1
Bth/þ þmiTmc mice, preservation of hearing was significant in comparison to hearing in controls for up to 21 weeks; however, by 30 weeks ABR thresholds in the Tmc1
Bth/þ þmiTmc mice increased ( Figure 5B ). In the two best-performing animals, hearing thresholds remained stable at 15-20 dB above the thresholds of wild-type C3HeB/ FeJ littermate controls for the entire study ( Figure 5B ). In these two animals, hearing thresholds remained at least 40 dB better than in untreated Tmc1
Bth/þ animals. In the two worst-performing animals, hearing protection was lost by 26 weeks. Frequency-specific effects were measured with tone-burst ABRs ( Figures 5C and 5D) Figure 5D , 13 weeks). The rate of progression was not increased in Tmc1 Bth/þ þmiSafe injected mice, supporting the nontraumatic nature of the trans-RWM injection at P0-P2.
In the left ears of Tmc1 Bth/þ þmiTmc mice, there was significant preservation of hearing at 8 and 16 kHz 4 weeks after treatment, although there was no protective effect at 32 kHz ( Figures 5D, 4 weeks). By 13 weeks after injection, the protective effect at 16 kHz was lost; however, at 8 kHz a significant protective effect still remained (Figures 5C and 5D, 13 weeks). In the two best-performing animals, hearing thresholds at 8 kHz were preserved throughout the entire study period (dashed blue line); thresholds were stable and only mildly higher than those of wild-type littermate controls (solid black line) ( Figure 5D , 4-35 weeks; Figure S5 ). We also measured 8 kHz wave I amplitudes at 4 weeks as a measure of synaptic integrity. The treated left ears in Tmc1
Bth/þ þmiTmc mice had smaller amplitudes overall than did those of wild-type littermate controls. Wave I amplitudes were even smaller in Tmc1 Bth/þ þmiSafe mice and continued to dampen at 8 weeks. In the Tmc1 Bth/þ þmiTmc mice, the wave I amplitudes remained stable ( Figures S6A  and S6B ). DPOAEs are an objective measure of OHC function and were recorded at the same time points as the ABRs. Consistent with prior reports, we found DPOAE recordings to be comparable between Tmc1
Bth/þ mice and wild-type controls, reflecting a high degree of OHC preservation in the cochlear apex 26 ( Figure 5E 
Bth/þ þmiSafe mice showed a sharp decline in DPOAEs in the ultra-high-frequency range, DPOAEs in Tmc1 Bth/þ þmiTmc mice were maintained ( Figures 5E, 8 weeks) . This difference persisted, consistent with some preservation of OHCs in the basal turn of the cochlea in Tmc1
Bth/þ þmiTmc mice ( Figure 5E,  4-35 weeks) .
In summary, a single injection of miTmc significantly slowed progression of hearing loss in Tmc1
Bth/þ mice for approximately 21 weeks. At the end of the 35-week study period, the two best-performing Tmc1 Bth/þ þmiTmc mice had hearing thresholds that were only 15-20 dB above thresholds for wild-type C3HeB/FeJ littermate controls. These thresholds were approximately 40 dB better than expected in the absence of treatment.
miTmc Improves Hair Cell Survival
The histological correlate of auditory function in Tmc1
Bth/þ mice is hair cell survival. To quantitate the effect of miTmc on hair cell survival, we counted hair cells in 0.25 mm segments from cochlear whole mounts in four groups: (1) wild-type littermates, (2) Tmc1 Bth/þ þmiTmc mice, (3)
Tmc1
Bth/þ þmiSafe mice, and (4) Tmc1 Bth/þ non-injected mice. Consistent with reported data, in Tmc1 Bth/þ mice IHC loss was more pronounced than OHC loss and occurred in a base-to-apex gradient. 26 By 35 weeks, we found complete IHC loss in the basal turn and 40%-50% IHC loss in the apical turn ( Figures 6A and 6B Bth/þ þmiTmc mice were greatest in the apical region of the cochleae (10%-20%), and visible gaps occurring in the mid-modiolar region (40%-50%) showed inter-animal variability. In the lower mid-modiolar to basal regions of the cochleae (60%-70%), the pattern of IHC loss was indistinguishable between Tmc1 Bth/þ þmiTmc mice and
Bth/þ and Tmc1
Bth/þ þmiSafe mice. When we compared the entire Tmc1
Bth/þþ miTmc cohort to the two best performers, we observed only a slight difference in mean IHC survival in the apical to mid-modiolar regions of the cochleae (10%-50%; Figure 6C ). Compared to Tmc1
Bth/þ þmiSafe animals, Tmc1
Bth/þ þmiTmc mice showed minimal improvement in OHC survival in the apical 10% of the cochleae and in the lower mid-modiolar to basal regions of the cochlea, although these differences were not significant. OHC survival was otherwise comparable between Tmc1
Bth/þ þmiTmc and Tmc1 Bth/þ animals ( Figure 6D ).
We also examined stereocilia-bundle morphology in surviving hair cells in both the best-performing and worstperforming Tmc1
Bth/þ þmiTmc mice alongside Tmc1
Bth/þ and wild-type controls at 35 weeks ( Figure S7 ). In the Tmc1 Bth/þ þmiTmc mice, stereocilia bundles appeared to be thinner but nevertheless well organized and comparable to those of wild-type controls in the apical regions; in the basal region, any remaining stereocilia bundles were sparse and distorted. This apex-to-base gradient of stereocilia-bundle degeneration is consistent with earlier observations in Tmc1 Bth/þ mice. 5, 27 In Tmc1 Bth/þ mice, fewer surviving hair cells remained, and in those cells, the stereocilia bundles were distorted or absent ( Figure S7 , Tmc1 Bth/þ ). We observed no difference between the two best performers and the entire cohort treated with Tmc1 Bth/þ þmiTmc ( Figure S7 ).
Discussion
This report demonstrates that using RNAi to suppress expression of an endogenous deafness-causing allele can slow progression of hearing loss. We selectively suppressed the Tmc1 c.1235T>A (p.Met412Lys) dominant gain-offunction allele in Tmc1 Bth/þ mice at an early developmental stage. We were able to prevent profound hearing loss from developing for over 35 weeks (the duration of the study) in some animals otherwise destined to have severe to profound levels of deafness across all frequencies by 17-21 weeks. Treatment with miTmc also appeared to have a particularly striking protective effect on hair cell survival. Compared to Tmc1
Bth/þ þmiSafe and Tmc1 Bth/þ non-injected mice,
Tmc1
Bth/þ þmiTmc mice showed significantly enhanced IHC survival in the apical turn of the cochlea. Although the reasons for enhanced IHC survival remain to be determined, these observations are consistent with both the pattern of rAAV2/9 transduction and audiometric data.
In the majority of Tmc1
Bth/þ þmiTmc mice, a single injection of miTmc maintained hearing acuity for~26 weeks. Thereafter, the protective effect of miTmc on hearing was variable, a result consistent with well-documented differences in the efficiency and longevity of viral transduction. 22, 28, 29 There are also reports of successful restoration of normal inner-ear morphology but failed restoration of auditory function after inner-ear gene therapy employing AAV vectors. Chien et al. attempted to restore hearing in deaf whirler (whirlin À/À ) mice with trans-RWM injections of AAV8-Whirlin, and although they demonstrated restored morphology of the stereocilia, hearing sensitivity was not rescued. 31 Similarly, attempts using AAV1-Gjb2 to restore The low rate of viral transduction appears to be the most common conclusion for unsuccessful restoration of hearing sensitivity and could be the reason for the variability observed in our study as well. Indeed, although we achieved high viral transduction in the apical turn and observed hearing preservation at 8 kHz, transduction in the lower turns was very low, and at 32 kHz, the progression of hearing loss was not affected. These observations, however, do not explain the hearing deterioration we documented in the majority of treated mice after 26 weeks.
The longevity of rAAV therapeutics is believed to maintain stable transgene expression for a year or longer, as noted in studies of human gene therapy with AAV2-hRPE65v2 in Leber's congenital amaurosis. 33 One explanation for the time-limited hearing preservation we observed could be the natural progression of OHC loss that occurs in Tmc1 Bth/þ mice in a base-to-apex gradient overtime, although this loss is minimal in the apical region at 20 weeks. 26 An alternate explanation could be the variability of RNAi in Tmc1
Bth/þ þmiTmc mice at the molecular level, which leads to early loss of the RNAi-mediated effect. Side effects of RNAi include miRNA off-target effects, saturation of miRNA endogenous machinery, and immune stimulation via siRNA. 34 A combination of these side effects could possibly lead to molecular changes at the hair cell level, although we did not observe structural damage, significant IHC loss, or signs of inflammation even in treated animals that were profoundly deaf at the end of the study, suggesting that miTmc gene therapy did not cause oto-toxicity at the cellular level. Further studies will be needed to improve OHC transduction and to investigate any long-term consequences of RNAi-mediated gene therapy at the molecular level. Missense mutations underlie 85% of all human autosomal-dominant non-syndromic hearing loss, raising the possibility that an RNAi-based therapeutic strategy could be broadly applicable to this type of hearing loss. 35 Targeting autosomal-dominant non-syndromic hearing loss would be attractive because this type of loss is postlingual and progressive, thus providing a large window of opportunity for surgical intervention with a miRNA-based genesilencing strategy. Prior to any clinical trial, however, several challenges must be addressed. First, although this and other studies attest to the value of mouse models for testing different forms of gene therapy directed at hearing preservation or restoration, 28, 36 because functional maturation of the cochlea occurs during the second postnatal week in mice and during the third trimester in humans, direct translation of these studies across species is not possible. Additional studies in rodents must focus on the age at injection, which remains a potential challenge given that transduction efficiency of inner-ear structures appears to be inversely related to the postnatal time of exposure. Target tissue must also be addressed because although HCs express one-third of all genes known to be associated with deafness 37 -which makes them excellent transduction candidates-efforts to effectively and selectively target other cells must be established. Route of injection and vector choice must be optimized. Because of the small volume of the inner ear, direct-injection techniques will limit the total number of viralgenome-containing particles per mililiter that can be delivered, suggesting that alternative approaches should be explored to permit higher total injection loads. These experiments will require testing a variety of vectors to define the injection route, injection time, and inner-ear cell specificity for each. Finally, the possibility that therapeutic intervention after hearing loss begins could improve some genetic types of deafness if irreversible damage has not occurred should be explored.
Many of these questions will be addressed with murine models of hearing loss, but ultimately proof-of-concept studies in non-human primates will be needed to confirm vector trophism for specific types of inner-ear cells in the absence of off-target effects. Clinical trials will then be possible. Their design might require the recruitment of persons with gene-specific or even mutation-specific types of hearing loss, a selection process that will be facilitated through genetic databases that many laboratories are maintaining on persons who receive comprehensive genetic testing as part of their clinical diagnostic evaluation for hearing impairment.
We believe that preventing hearing loss in an organ destined to fail presents fewer challenges than restoring function in a cochlea that has already undergone substantial degenerative changes. Thus, although using gene therapy to replace lost hair cells or regrow inner-ear architecture is likely to be exceedingly difficult, its use for replacing defective genes, suppressing a deafness-causing allele, or correcting abnormal splicing before cochlear damage is rampant might be more feasible. Because substantial challenges remain in using gene therapy to restore the functional integrity of this unique and complex organ, we believe that efforts to prevent autosomal-dominant nonsyndromic hearing loss warrant a concerted effort by the research community as an example of ''low-hanging fruit.''
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